Literature DB >> 25400779

Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient's survival.

Jian Liu1, Lujun Chen1, Haifeng Deng1, Bin Xu1, Min Li1, Xiao Zheng1, Changping Wu1, Jingting Jiang1.   

Abstract

The epithelial-mesenchymal transition (EMT) is an essential step in invasion and metastasis of human cancers. Identification of EMT status would help us to properly understand the mechanism of cancer metastasis and progression. In the present study, tissue microarray and immunohistochemical staining of two important markers, E-cadherin and Vimentin, were used to characterize the EMT status in human esophageal cancer. We selected the appropriate cut-off values of expression levels of E-cadherin and Vimentin, and found 63 out of 105 cases of esophageal cancers underwent EMT. And we also found that in the subgroup with (T₃ + T₄), the ratio of patients undergoing EMT was significantly higher than that in the subgroup with (T₁ + T₂) (P = 0.0097), and in the subgroup with metastasis, the ratio of patients undergoing EMT was significantly higher than that in the subgroup with no metastasis (P = 0.0253). The log-rank survival analysis showed that the overall survival rate of the patients undergoing EMT was significantly poorer than that of the patients with wide type status (P = 0.0278, HR = 2.470, 95% CI: 1.971~2.970). In the COX model analysis, we also found that the EMT status of the esophageal cancer patients could be used as an independent risk factor for the prediction of prognosis of this malignancy (P = 0.026, HR = 2.306, 95% CI: 1.103~4.824). Thus, our present study successfully established a method by using tissue microarray and the markers, E-cadherin and Vimentin, to conveniently and properly identify the EMT status in human esophageal cancer, and revealed that the EMT status significantly associated with invasion, metastasis and prognosis in this malignancy.

Entities:  

Keywords:  Epithelial-to-mesenchymal transition; esophageal cancer; immunohistochemistry; tissue microarray

Mesh:

Substances:

Year:  2014        PMID: 25400779      PMCID: PMC4230146     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

1.  Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.

Authors:  Jun Zhao; Dahai Dong; Lingling Sun; Guiming Zhang; Lijiang Sun
Journal:  Int Braz J Urol       Date:  2014 Mar-Apr       Impact factor: 1.541

2.  Different intermediate-sized filaments distinguished by immunofluorescence microscopy.

Authors:  W W Franke; E Schmid; M Osborn; K Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

3.  SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells.

Authors:  Michael Pohl; Yvonne Radacz; Nicole Pawlik; Anna Schoeneck; Stephan E Baldus; Johanna Munding; Wolff Schmiegel; Irmgard Schwarte-Waldhoff; Anke Reinacher-Schick
Journal:  Anticancer Res       Date:  2010-07       Impact factor: 2.480

Review 4.  Fibroblasts in cancer.

Authors:  Raghu Kalluri; Michael Zeisberg
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

5.  Clinicopathological significance of Sip1-associated epithelial mesenchymal transition in non-small cell lung cancer progression.

Authors:  Naoko Miura; Tokujiro Yano; Fumihiro Shoji; Daigo Kawano; Tomoyoshi Takenaka; Kensaku Ito; Yosuke Morodomi; Ichiro Yoshino; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.

Authors:  Chie Kudo-Saito; Hiromi Shirako; Tadashi Takeuchi; Yutaka Kawakami
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast.

Authors:  Chandra P Prasad; Gayatri Rath; Sandeep Mathur; Dinesh Bhatnagar; Rajinder Parshad; Ranju Ralhan
Journal:  BMC Cancer       Date:  2009-09-14       Impact factor: 4.430

9.  E-cadherin repression contributes to c-Myc-induced epithelial cell transformation.

Authors:  V H Cowling; M D Cole
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

10.  Contribution of nestin positive esophageal squamous cancer cells on malignant proliferation, apoptosis, and poor prognosis.

Authors:  Beilong Zhong; Tao Wang; Zhenguang Chen; Xueping Lun; Jinli Zhang; Sannv Zheng; Weilin Yang; Weiqiang Li; Andy Peng Xiang
Journal:  Cancer Cell Int       Date:  2014-06-20       Impact factor: 5.722

View more
  10 in total

1.  Cancer stem-like cells contribute to paclitaxel resistance in esophageal squamous cell carcinoma.

Authors:  Yanru Shen; Lihui Yang; Lei Li
Journal:  Int J Clin Exp Pathol       Date:  2022-04-15

2.  Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.

Authors:  Reihaneh Alsadat Mahmoudian; Maryam Lotfi Gharaie; Mohammad Reza Abbaszadegan; Ali Alasti; Mohammad Mahdi Forghanifard; Atena Mansouri; Mehran Gholamin
Journal:  Mol Cell Biochem       Date:  2021-02-19       Impact factor: 3.396

3.  Modulation of E-cadherin expression promotes migration ability of esophageal cancer cells.

Authors:  Shujun Li; Xuebo Qin; Song Chai; Changbao Qu; Xiaolu Wang; Helin Zhang
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

4.  Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Satoshi Tsutsumi; Hiroshi Saeki; Yuichiro Nakashima; Shuhei Ito; Eiji Oki; Masaru Morita; Yoshinao Oda; Shinji Okano; Yoshihiko Maehara
Journal:  Cancer Sci       Date:  2017-05-25       Impact factor: 6.716

5.  Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.

Authors:  Ulrich A Hirt; Irene C Waizenegger; Norbert Schweifer; Christian Haslinger; Daniel Gerlach; Jürgen Braunger; Ulrike Weyer-Czernilofsky; Heinz Stadtmüller; Ioannis Sapountzis; Gerd Bader; Andreas Zoephel; Bojan Bister; Anke Baum; Jens Quant; Norbert Kraut; Pilar Garin-Chesa; Günther R Adolf
Journal:  Oncogenesis       Date:  2018-02-23       Impact factor: 7.485

Review 6.  Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.

Authors:  Kevin Dzobo; Dimakatso Alice Senthebane; Chelene Ganz; Nicholas Ekow Thomford; Ambroise Wonkam; Collet Dandara
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

Review 7.  Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.

Authors:  Richard Harrop; Eric O'Neill; Peter L Stern
Journal:  Ther Adv Vaccines Immunother       Date:  2019-01-25

8.  STAT1/IFIT2 signaling pathway is involved in PD-L1-mediated epithelial-to-mesenchymal transition in human esophageal cancer.

Authors:  J Chen; Y Liu; Y Zhu; Y Chen; J Feng; T Jiang; X Zheng; L Chen; J Jiang
Journal:  Clin Transl Oncol       Date:  2022-02-02       Impact factor: 3.340

9.  A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516.

Authors:  Kazuya Arai; Takanori Eguchi; M Mamunur Rahman; Ruriko Sakamoto; Norio Masuda; Tetsuya Nakatsura; Stuart K Calderwood; Ken-Ichi Kozaki; Manabu Itoh
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

10.  Expression of CCR6 in esophageal squamous cell carcinoma and its effects on epithelial-to-mesenchymal transition.

Authors:  Jian Liu; Xiao Zheng; Haifeng Deng; Bin Xu; Lujun Chen; Qi Wang; Qi Zhou; Dachuan Zhang; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2017-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.